El antecedente fundamental de las nuevas guías sobre colesterol | 17 FEB 14

Tres motivos para abandonar al LDL como objetivo terapéutico

Carta abierta al comité ATP fundamentando la necesidad de que las nuevas recomendaciones abandonen el paradigma del tratamiento según el objetivo de C-LDL.
Autor/a: Dres. Hayward RA, Krumholz HM. Circulaton. Cardiovascular Quality Outcomes 2012;5:25
INDICE:  1.  | 2. 

1. National Heart, Lung, and Blood Institute. Cardiovascular risk reduction guidelines in adults: cholesterol guideline update (ATP IV); hypertension guideline update (JNC 8); obesity guideline update (Obesity 2); integrated cardiovascular risk reduction guideline. http://www.nhlbi.nih.gov/guidelines/cvd_adult/background.htm. Accessed December 12, 2011.
2. Krumholz HM. Medicine in the era of outcomes measurement. Circ Cardiovasc Qual Outcomes . 2009; 2:141–143.
3. Krumholz HM. Medicine should be more like Missouri. Circ Cardiovasc Qual Outcomes . 2009; 2:289–291.
4. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med .2011; 154:627–634.
5. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med. 2006; 145:520–530.
6. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010; 152:69–77.
7. Sussman JB, Vijan S, Choi H, Hayward RA. Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes . 2011; 4:268–275.
8. Timbie JW, Hayward RA, Vijan S. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. Arch Intern Med . 2010; 170:1037–1044.
9. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, Furberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes  2011; 4:337–345.
10. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation . 1991;83: 356–362.
11. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation . 2008; 118: 2243–2251.
12. University of Oxford. UKPDS Risk Engine. http://www.dtu.ox.ac.uk/ riskengine/. Accessed December 12, 2011.
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7–22.
14. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet . 2005; 366: 1267–1278.
15. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes . 2009; 2:616–623.
16. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol . 2006; 97:33A–41A.
17. Krumholz HM, Hayward RA. Shifting views on lipid lowering therapy. BMJ . 2010; 341:c3531.
18. Carey J. Do cholesterol drugs do any good? Bloomberg Businessweek. January 17, 2008. http://www.businessweek.com/magazine/content/08_04/
b4068052092994.htm?chantop news_top news index_top story. Accessed December 12, 2011.
19. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 2004; 110:227–239.
20. Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics . 2008; 122:198–208.
21. National Heart, Lung, and Blood Institute. Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. http://www.nhlbi.nih.gov/health/prof/heart/other/accord/q_a.htm. March 15, 2010. Accessed December 12, 2011.
22. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007; 357: 2109–2122.
23. Department of Health and Human Services. Findings from the WHI postmenopausal hormone therapy trials. http://www.nhlbi.nih.gov/whi/. September 21, 2010. Accessed December 12, 2011.
24. Hayward RA. All-or-nothing treatment targets make bad performance measures. Am J Manag Care . 2007; 13:126–128.
25. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A. Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 2008; 148:656–661



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024